---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-088584"
form_type: "8-K"
ticker: "IRWD"
cik: "0001446847"
company_name: "IRONWOOD PHARMACEUTICALS INC"
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T01:31:13.079129+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Ironwood posts Q2 GAAP net loss of $1.06B on acquisition costs; LINZESS sales +9%

## Summary
- GAAP net loss attributable to Ironwood of $1.06B, or $6.84/share diluted, primarily from VectivBio acquisition.
- Total revenues $107.4M, up 10% YoY; LINZESS U.S. net sales $270M, +9% YoY.
- FDA approved LINZESS for pediatric FC ages 6-17 in June, expanding addressable market.
- Acquired VectivBio for apraglutide (SBS-IF); STARS Phase III enrollment complete, data March 2024.
- Raised full-year 2023 guidance: LINZESS net sales $1.055-1.075B, Ironwood revenue $435-455M.

## SEC filing metadata
- accession: 0001104659-23-088584
- form_type: 8-K
- ticker: IRWD
- cik: 0001446847
- company_name: IRONWOOD PHARMACEUTICALS INC
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1446847/000110465923088584/0001104659-23-088584-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1446847/000110465923088584/tm2323024d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-088584
- JSON: https://secwatch.observer/filing/0001104659-23-088584.json
- Plain text: https://secwatch.observer/filing/0001104659-23-088584.txt

## Key facts
- Earnings Releases
  IRONWOOD PHARMACEUTICALS INC reported second quarter 2023 results: revenue $107,382, net income $(1,089,478), EPS $(6.84) per share – basic. Guidance raised.
  - Period: second quarter 2023
  - Revenue: $107,382
  - Net income: $(1,089,478)
  - EPS: $(6.84) per share – basic
  - Guidance: raised
  - Result: reported results
  source text: position, and grow Ironwood’s leadership within GI.” Second Quarter 2023 Financial Highlights 1 (in thousands, except for per share amounts) 2Q 2023 2Q 2022 Total revenues $ 107,382 $ 97,231 Total operating expenses 2 1,190,521 41,576 GAAP net income (loss) 2 (1,089,478 ) 37,080 GAAP net income (loss) attributable to Ironwood Pharmaceuticals, Inc. 2
  evidence_url: https://www.sec.gov/Archives/edgar/data/1446847/000110465923088584/0001104659-23-088584-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.